{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T16:54:53Z","timestamp":1789750493260,"version":"4.0.1"},"reference-count":39,"publisher":"American Medical Association (AMA)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"DOI":"10.1001\/jamanetworkopen.2020.11818","type":"journal-article","created":{"date-parts":[[2020,9,21]],"date-time":"2020-09-21T18:39:31Z","timestamp":1600713571000},"page":"e2011818","source":"Crossref","is-referenced-by-count":36,"title":["Evaluation of Programmed Death Ligand 1 (<i>PD-L1<\/i>) Gene Amplification and Response to Nivolumab Monotherapy in Non\u2013small Cell Lung Cancer"],"prefix":"10.1001","volume":"3","author":[{"given":"Yusuke","family":"Inoue","sequence":"first","affiliation":[{"name":"Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan"},{"name":"Department of Tumor Pathology, Hamamatsu University School of Medicine, Hamamatsu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuhiro","family":"Yoshimura","sequence":"additional","affiliation":[{"name":"Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan"},{"name":"Department of Tumor Pathology, Hamamatsu University School of Medicine, Hamamatsu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Nishimoto","sequence":"additional","affiliation":[{"name":"Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Inui","sequence":"additional","affiliation":[{"name":"Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan"},{"name":"Clinical Pharmacology and Therapeutics, Hamamatsu University School of Medicine, Hamamatsu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masato","family":"Karayama","sequence":"additional","affiliation":[{"name":"Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan"},{"name":"Department of Clinical Oncology, Hamamatsu University School of Medicine, Hamamatsu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Yasui","sequence":"additional","affiliation":[{"name":"Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hironao","family":"Hozumi","sequence":"additional","affiliation":[{"name":"Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuzo","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuki","family":"Furuhashi","sequence":"additional","affiliation":[{"name":"Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoyuki","family":"Fujisawa","sequence":"additional","affiliation":[{"name":"Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriyuki","family":"Enomoto","sequence":"additional","affiliation":[{"name":"Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaro","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiro","family":"Asada","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Shizuoka General Hospital, Shizuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiro","family":"Uto","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Iwata City Hospital, Iwata, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masato","family":"Fujii","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Shizuoka City Shizuoka Hospital, Shizuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Matsui","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Seirei Mikatahara General Hospital, Hamamatsu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shun","family":"Matsuura","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Fujieda Municipal General Hospital, Fujieda, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dai","family":"Hashimoto","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Medicine, Seirei Hamamatsu General Hospital, Hamamatsu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikio","family":"Toyoshima","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Hamamatsu Rosai Hospital, Hamamatsu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Kusagaya","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Shizuoka Saiseikai General Hospital, Shizuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Matsuda","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Japanese Red Cross Shizuoka Hospital, Shizuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nao","family":"Inami","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Shizuoka City Shimizu Hospital, Shizuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Kaida","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Ensyu Hospital, Hamamatsu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuru","family":"Niwa","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Hamamatsu Medical Center, Hamamatsu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Ito","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Tenryu Hospital, National Hospital Organization, Hamamatsu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruhiko","family":"Sugimura","sequence":"additional","affiliation":[{"name":"Department of Tumor Pathology, Hamamatsu University School of Medicine, Hamamatsu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takafumi","family":"Suda","sequence":"additional","affiliation":[{"name":"Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2020,9,21]]},"reference":[{"issue":"2","key":"zoi200458r1","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non\u2013small cell lung cancer.","volume":"373","author":"Brahmer","year":"2015","journal-title":"N Engl J Med"},{"issue":"17","key":"zoi200458r2","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non\u2013small cell lung cancer.","volume":"373","author":"Borghaei","year":"2015","journal-title":"N Engl J Med"},{"issue":"10027","key":"zoi200458r3","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","article-title":"Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.","volume":"387","author":"Herbst","year":"2016","journal-title":"Lancet"},{"issue":"10066","key":"zoi200458r4","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/S0140-6736(16)32517-X","article-title":"Atezolizumab versus docetaxel in patients with previously treated non\u2013small cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.","volume":"389","author":"Rittmeyer","year":"2017","journal-title":"Lancet"},{"issue":"19","key":"zoi200458r5","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non\u2013small cell lung cancer.","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"issue":"20","key":"zoi200458r6","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab after chemoradiotherapy in stage III non\u2013small-cell lung cancer.","volume":"377","author":"Antonia","year":"2017","journal-title":"N Engl J Med"},{"issue":"10","key":"zoi200458r7","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1001\/jamaoncol.2016.1051","article-title":"Treatment of the immune-related adverse effects of immune checkpoint inhibitors: a review.","volume":"2","author":"Friedman","year":"2016","journal-title":"JAMA Oncol"},{"issue":"8","key":"zoi200458r8","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1158\/1078-0432.CCR-16-1741","article-title":"Hyperprogressive disease is a new pattern of progression in cancer patients treated by anti-PD-1\/PD-L1.","volume":"23","author":"Champiat","year":"2017","journal-title":"Clin Cancer Res"},{"key":"zoi200458r9","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.ejca.2018.11.002","article-title":"Predictive biomarkers of response for immune checkpoint inhibitors in non-small-cell lung cancer.","volume":"106","author":"Prelaj","year":"2019","journal-title":"Eur J Cancer"},{"issue":"6349","key":"zoi200458r10","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1126\/science.aan6733","article-title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.","volume":"357","author":"Le","year":"2017","journal-title":"Science"},{"issue":"26","key":"zoi200458r11","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency.","volume":"372","author":"Le","year":"2015","journal-title":"N Engl J Med"},{"issue":"7","key":"zoi200458r12","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1200\/JCO.2017.75.3384","article-title":"Molecular determinants of response to anti-programmed cell death (PD)-1 and anti-programmed death-ligand 1 (PD-L1) blockade in patients with non\u2013small cell lung cancer profiled with targeted next-generation sequencing.","volume":"36","author":"Rizvi","year":"2018","journal-title":"J Clin Oncol"},{"issue":"5","key":"zoi200458r13","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/j.ccell.2018.03.018","article-title":"Genomic features of response to combination immunotherapy in patients with advanced non\u2013small cell lung cancer.","volume":"33","author":"Hellmann","year":"2018","journal-title":"Cancer Cell"},{"issue":"6230","key":"zoi200458r14","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1126\/science.aaa1348","article-title":"Cancer immunology: mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.","volume":"348","author":"Rizvi","year":"2015","journal-title":"Science"},{"issue":"7528","key":"zoi200458r15","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/nature13954","article-title":"PD-1 blockade induces responses by inhibiting adaptive immune resistance.","volume":"515","author":"Tumeh","year":"2014","journal-title":"Nature"},{"issue":"4","key":"zoi200458r16","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/j.cell.2017.09.028","article-title":"Tumor and microenvironment evolution during immunotherapy with nivolumab.","volume":"171","author":"Riaz","year":"2017","journal-title":"Cell"},{"issue":"7","key":"zoi200458r17","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1038\/s41591-018-0057-z","article-title":"A transcriptionally and functionally distinct PD-1+ CD8+ T cell pool with predictive potential in non\u2013small cell lung cancer treated with PD-1 blockade.","volume":"24","author":"Thommen","year":"2018","journal-title":"Nat Med"},{"issue":"8","key":"zoi200458r18","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1001\/jamaoncol.2019.1549","article-title":"Comparison of biomarker modalities for predicting response to PD-1\/PD-L1 checkpoint blockade: a systematic review and meta-analysis.","volume":"5","author":"Lu","year":"2019","journal-title":"JAMA Oncol"},{"issue":"8","key":"zoi200458r19","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1002\/gcc.v55.8","article-title":"Pan-cancer analysis of copy number changes in programmed death-ligand 1 (PD-L1, CD274)\u2014associations with gene expression, mutational load, and survival.","volume":"55","author":"Budczies","year":"2016","journal-title":"Genes Chromosomes Cancer"},{"issue":"23","key":"zoi200458r20","doi-asserted-by":"publisher","first-page":"2690","DOI":"10.1200\/JCO.2016.66.4482","article-title":"PD-L1 and PD-L2 genetic alterations define classical Hodgkin lymphoma and predict outcome.","volume":"34","author":"Roemer","year":"2016","journal-title":"J Clin Oncol"},{"issue":"28","key":"zoi200458r21","doi-asserted-by":"publisher","first-page":"26483","DOI":"10.18632\/oncotarget.v6i28","article-title":"Genomic amplification of 9p24.1 targeting JAK2, PD-L1, and PD-L2 is enriched in high-risk triple negative breast cancer.","volume":"6","author":"Barrett","year":"2015","journal-title":"Oncotarget"},{"issue":"22","key":"zoi200458r22","doi-asserted-by":"publisher","first-page":"32113","DOI":"10.18632\/oncotarget.v7i22","article-title":"Clinical significance of PD-L1 and PD-L2 copy number gains in non\u2013small cell lung cancer.","volume":"7","author":"Inoue","year":"2016","journal-title":"Oncotarget"},{"issue":"1","key":"zoi200458r23","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.jtho.2015.09.010","article-title":"PD-L1 Is upregulated by simultaneous amplification of the PD-L1 and JAK2 genes in non\u2013small cell lung cancer.","volume":"11","author":"Ikeda","year":"2016","journal-title":"J Thorac Oncol"},{"issue":"5","key":"zoi200458r24","doi-asserted-by":"publisher","first-page":"e1205","DOI":"10.1016\/j.clbc.2018.05.006","article-title":"JAK2 and PD-L1 amplification enhance the dynamic expression of PD-L1 in triple-negative Breast Cancer.","volume":"18","author":"Chen","year":"2018","journal-title":"Clin Breast Cancer"},{"issue":"9","key":"zoi200458r25","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.1158\/1078-0432.CCR-15-2834","article-title":"Pan-cancer immunogenomic perspective on the tumor microenvironment based on PD-L1 and CD8 T-Cell infiltration.","volume":"22","author":"Ock","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"20","key":"zoi200458r26","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.","volume":"310","author":"World Medical Association","year":"2013","journal-title":"JAMA"},{"issue":"10","key":"zoi200458r27","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0040296","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies.","volume":"4","author":"von Elm","year":"2007","journal-title":"PLoS Med"},{"issue":"4","key":"zoi200458r28","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1093\/carcin\/bgn046","article-title":"Detection of chromosome changes in pathology archives: an application of microwave-assisted fluorescence in situ hybridization to human carcinogenesis studies.","volume":"29","author":"Sugimura","year":"2008","journal-title":"Carcinogenesis"},{"issue":"3","key":"zoi200458r29","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics.","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"zoi200458r30","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1158\/2159-8290.CD-18-0099","article-title":"STK11\/LKB1 mutations and PD-1 inhibitor resistance in KRAS-mutant lung adenocarcinoma.","volume":"8","author":"Skoulidis","year":"2018","journal-title":"Cancer Discov"},{"issue":"9","key":"zoi200458r31","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1038\/s41588-018-0200-2","article-title":"Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors.","volume":"50","author":"Miao","year":"2018","journal-title":"Nat Genet"},{"issue":"4","key":"zoi200458r32","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin\u2019s lymphoma.","volume":"372","author":"Ansell","year":"2015","journal-title":"N Engl J Med"},{"issue":"17","key":"zoi200458r33","doi-asserted-by":"publisher","first-page":"4309","DOI":"10.1158\/1078-0432.CCR-16-0903","article-title":"Mutational landscape and sensitivity to immune checkpoint blockers.","volume":"22","author":"Chabanon","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"9","key":"zoi200458r34","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1001\/jamaoncol.2018.1701","article-title":"Prevalence of PDL1 amplification and preliminary response to immune checkpoint blockade in solid tumors.","volume":"4","author":"Goodman","year":"2018","journal-title":"JAMA Oncol"},{"issue":"3","key":"zoi200458r35","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/s41591-019-0382-x","article-title":"Genomic correlates of response to immune checkpoint blockade.","volume":"25","author":"Keenan","year":"2019","journal-title":"Nat Med"},{"issue":"17","key":"zoi200458r36","doi-asserted-by":"publisher","first-page":"3268","DOI":"10.1182\/blood-2010-05-282780","article-title":"Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma.","volume":"116","author":"Green","year":"2010","journal-title":"Blood"},{"key":"zoi200458r37","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.lungcan.2019.06.002","article-title":"Heterogeneity analysis of PD-L1 expression and copy number status in EBUS-TBNA biopsy specimens of non\u2013small cell lung cancer: comparative assessment of primary and metastatic sites.","volume":"134","author":"Yoshimura","year":"2019","journal-title":"Lung Cancer"},{"issue":"12","key":"zoi200458r38","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1200\/JCO.18.01042","article-title":"First-line nivolumab plus ipilimumab in advanced non\u2013small-cell lung cancer (CheckMate 568): outcomes by programmed death ligand 1 and tumor mutational burden as biomarkers.","volume":"37","author":"Ready","year":"2019","journal-title":"J Clin Oncol"},{"issue":"6322","key":"zoi200458r39","doi-asserted-by":"crossref","DOI":"10.1126\/science.aaf8399","article-title":"Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy.","volume":"355","author":"Davoli","year":"2017","journal-title":"Science"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2770741\/inoue_2020_oi_200458_1599757728.18832.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,21]],"date-time":"2020-09-21T18:39:34Z","timestamp":1600713574000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2770741"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,21]]},"references-count":39,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,9,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2020.11818","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,21]]}}}